Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial - Kyriakopoulos, Christos E.; Chen, Yu-Hui; Carducci, Michael A.; Liu, Glenn; Jarrard, David F.; Hahn, Noah M.; Shevrin, Daniel H.; Dreicer, Robert; Hussain, Maha; Eisenberger, Mario; Kohli, Manish; Plimack, Elizabeth R.; et al. (Journal of clinical oncology, 2018)
Keywords: Androgen Antagonists - administration & dosage; Androgen Antagonists - adverse effects; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Docetaxel - administration & dosage; Docetaxel - adverse effects; Humans; Male; Neoplasm Metastasis; Neoplasms, Hormone-Dependent - drug therapy; Neoplasms, Hormone-Dependent - mortality; Neoplasms, Hormone-Dependent - pathology; ORIGINAL REPORTS; Prostatic Neoplasms - drug therapy; Prostatic Neoplasms - mortality; Prostatic Neoplasms - pathology; Time Factors; Treatment Outcome